This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how DBV Technologies S.A. (DBVT) and ProPhase Labs, Inc. (PRPH) have performed compared to their sector so far this year.
ProPhase Labs, Inc. (PRPH) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of 233.33% and 28.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of -26.47% and 92.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ProPhase Labs, Inc. (PRPH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) closed at $10.47 in the latest trading session, marking a -1.87% move from the prior day.
Strength Seen in ProPhase Labs, Inc. (PRPH): Can Its 8% Jump Turn into More Strength?
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks.com featured highlights include USA Truck, Franklin Covey, ProPhase Labs, Daqo New Energy and The Chefs' Warehouse
by Zacks Equity Research
USA Truck, Franklin Covey, ProPhase Labs, Daqo New Energy and The Chefs' Warehouse are part of zacks screen of the week article.
5 Stocks With Recent Price Strength for a Steady Portfolio
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are USAK, FC, PRPH, DQ and CHEF.
ProPhase Labs, Inc. (PRPH) Soars 9.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and ProPhase Labs, Inc. (PRPH) have performed compared to their sector so far this year.
ProPhase Labs, Inc. (PRPH) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ProPhase Labs, Inc. (PRPH) Surges 7.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Is ProPhase Labs (PRPH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how ProPhase Labs, Inc. (PRPH) and RVL Pharmaceuticals PLC (RVLP) have performed compared to their sector so far this year.
Reata (RETA) Up More Than 12% YTD: What's Driving the Rally?
by Zacks Equity Research
Reata's (RETA) prospects are likely to improve following the potential approval of its lead candidate, omaveloxolone, expected by the end of 2022 is likely driving its share price.
Axcella (AXLA) Up on Decision to Prioritize Long-COVID Program
by Zacks Equity Research
Axcella (AXLA) re-prioritizes its clinical portfolio to focus on the development of AXA1125 targeting long COVID and NASH. It also suspends the development of AXA1665 to focus resources on AXA1125 studies.
Reata (RETA) Friedreich's Ataxia NDA Gets Priority Review
by Zacks Equity Research
Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. The FDA grants priority review to the NDA for the same. Stock rises.
Esperion (ESPR) Up More Than 12% YTD: What's Driving the Rally?
by Zacks Equity Research
Esperion's (ESPR) marketed drugs are the key drivers of the stock. Sales of the drugs increase more than 100% during the first quarter. Strong sales growth is expected to continue in 2022 as well as 2023.
Has ProPhase Labs (PRPH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how ProPhase Labs, Inc. (PRPH) and RVL Pharmaceuticals PLC (RVLP) have performed compared to their sector so far this year.
United Therapeutics (UTHR) Gains on Tyvaso DPI Approval
by Zacks Equity Research
The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil. Stock gains 8.8%.
ProPhase Labs, Inc. (PRPH) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for May 24th
by Zacks Equity Research
PRPH, GOGL, and ERF made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 24, 2022.
ProPhase Labs, Inc. (PRPH) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of 74.36% and 95.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 19.05% and 120.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Q1 Earnings & Sales Beat, Stock Up
by Zacks Equity Research
United Therapeutics' (UTHR) first-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -86.54% and 49.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?